Small-Cap PMV Pharmaceuticals Cancer Drug Shows Confirmed Responses In 8 Tumor Types

Core Insights - PMV Pharmaceuticals, Inc. released interim data from the Phase 2 pivotal portion of the PYNNACLE clinical trial evaluating rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation [1] Efficacy - Confirmed responses were observed in patients with TP53 Y220C mutated and KRAS wild-type tumors across eight tumor types, with an overall response rate (ORR) of 33% [2] - Specific ORRs included: - Ovarian cancer: 43% ORR (19/44 patients, including one confirmed complete response and 17 confirmed partial responses) [3] - Breast cancer: 18% ORR (2/11 patients) [3] - Endometrial cancer: 60% ORR (3/5 patients, including one unconfirmed partial response) [3] - Lung cancer: 22% ORR (4/18 patients, including three unconfirmed partial responses) [3] - Other solid tumors: 21% ORR (4/19 patients) [3] - The median time to response across all cohorts was 1.4 months, with a median duration of response of 6.2 months [3] - In the ovarian cancer cohort, the median time to response was 1.3 months, and the median duration of response was 7.6 months [3] Safety - Treatment-related adverse events (TRAEs) were primarily grade 1-2, with the most frequent TRAEs (>15%) being nausea, fatigue, increased blood creatinine, and increased alanine aminotransferase [4] Regulatory Update - PMV Pharma received feedback from the U.S. Food and Drug Administration (FDA) regarding the initial New Drug Application (NDA) submission strategy for platinum-resistant/refractory ovarian cancer [5] - The company plans to enroll an additional 20-25 platinum-resistant/refractory ovarian cancer patients by the end of Q1 2026 [5] - An NDA submission for platinum-resistant/refractory ovarian cancer is planned by the end of Q1 2027 [6] Price Action - PMVP stock is down 23.30% at $1.23 as of the last check on Wednesday [6]